248
Participants
Start Date
December 3, 2015
Primary Completion Date
May 31, 2017
Study Completion Date
September 6, 2019
Anetumab ravtansine (BAY94-9343)
Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.
Vinorelbine
Starting dose: 30mg/m\^2 administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.
Bruxelles - Brussel
St Leonards
Edegem
Leuven
Richmond
Liège
Woolloogabba
Adelaide
Nedlands
Ghent
Sint-Niklaas
New York
Turin
Marseille
Caen
A Coruña
Milan
Milan
Turku
Bethesda
Monza Brianza
Bergamo
Eskişehir
Durham
Madrid
Málaga
Bordeaux
Pordenone
Tampa
Istanbul
Cleveland
Malatya
Siena
Rochester
Lille
Chicago
Chicago
Vaasa
Pierre-Bénite
New Orleans
Paris
Paris
Dallas
Houston
Aurora
Yekaterinburg
Omsk
La Jolla
Norwich
Buffalo
Calgary
Hamilton
London
Toronto
Helsinki
Amsterdam
Rotterdam
Gdansk
Krakow
Krakow
Szczecin
Seoul
Seoul
Alicante
Barcelona
Adana
Ankara
Yenimahalle
Plymouth
Maidstone
Leicester
Glasgow
London
Manchester
Newcastle upon Tyne
Lead Sponsor
ImmunoGen and MorphoSys
UNKNOWN
Bayer
INDUSTRY